Adina Turcu-Stiolica

Dr. Adina Turcu-Stiolica

University of Medicine and Pharmacy of Craiova
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Value in Health
Verified
Journal Article
Closed access
PPPriti P. Pednekar
Priti P. Pednekar
TÁTamás Ágh
Tamás Ágh
MMMaria Malmenäs
Maria Malmenäs
ARAmit D. Raval
Amit D. Raval
BBBryan M. Bennett
Bryan M. Bennett
APAndrew M. Peterson
Andrew M. Peterson

28 January 2020 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
MCMarcin Czech
Marcin Czech
ABAleksandra Baran-Kooiker
Aleksandra Baran-Kooiker
KAKagan Atikeler
Kagan Atikeler
MDMaria Demirtshyan
Maria Demirtshyan
KGKamilla Gaitova
Kamilla Gaitova
JSJolanta Sykut-Cegielska
Jolanta Sykut-Cegielska
Background: Despite international initiatives on collaboration within the field of rare diseases, patient access to orphan medicinal products (OMPs) and healthcare services differ greatly between countries. This study aimed to create a comprehensive and in-depth overview of rare diseases policies and reimbursement of OMPs in a selection of 12 countries in the Western Eurasian region: Armenia, France, Germany, Kazakhstan, Latvia, The Netherlands, Poland, Romania, Russia, Turkey, Ukraine, and the United Kingdom. Methods: A systematic literature review was performed and an analysis of publicly available legislative and rare disease health policy data was undertaken in five focus areas: rare disease definition, newborn screening, registries, national plans, access to/reimbursement of OMPs. Results: Screening programs are broadly implemented but the number of screened diseases differs significantly (2–35 diseases), either between EU and non-EU countries, between EU member states and sometimes even within a single country. In most countries rare disease registries are operating with regional, national, European or worldwide coverage. The number of rare disease registries is growing, as a result of the National Plans (EU) and increased international scientific cooperation. France, Russia, and Poland have a centrally acting registry. National plans are present in all EU countries but implementation varies and is ongoing. The number of reimbursed OMPs in the selected countries ranges from nearly all available OMPs in the Netherlands, Germany, and France to zero in Armenia. Reimbursement rules differ considerably regionally and a trend is observed of reimbursement conditions getting stricter for expensive (orphan) drugs. Discussion: Inequality in patient access to new OMPs still exists due to variations in national policies, healthcare budgets, health insurance, and reimbursement systems. The observed differences are challenging for rare disease patients, health authorities and manufacturers alike. Progress can be seen, however, and international cooperation and harmonization is slowly but steadily expanding in the rare disease arena.

9 July 2020 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
DCDana Alexandra Ciobanu
Dana Alexandra Ciobanu
IPIoan Sabin Poenariu
Ioan Sabin Poenariu
LCLaura-Ioana Crînguș
Laura-Ioana Crînguș
FVFlorentin Ananu Vreju
Florentin Ananu Vreju
Adina Turcu-StiolicaAdina Turcu-Stiolica
Adina Turcu-Stiolica
ABAndreea Lili Barbulescu
Andreea Lili Barbulescu
Rheumatoid arthritis (RA) is classified as an inflammatory, chronic autoimmune and disabling disease based on the intricate interplay between environmental and genetic factors. With a prevalence ranging from 0.3 to 1%, RA is the most prevalent inflammatory joint disease observed in adults. Disruption of immune tolerance becomes evident when abnormal stimulation of the innate and adaptive immune system occurs. This cascade of events causes persistent joint inflammation, proliferative synovitis and, ultimately, damage of the underlying cartilage as well as the subchondral bone, leading to permanent joint destruction, deformity and subsequent loss of function. With cytokines being the key to a multitude of biological processes, including inflammation, hematopoiesis and overall immune response, one must inevitably look at the main pathways through which a significant number of those molecules exert their function. Janus kinase/signal transducers and activators of transcription (JAK/STATs) represent one such pathway and, recently, JAK inhibitors (JAKinibs) have shown promise in the treatment of several inflammatory diseases, including RA. This narrative review focuses on the intricate signaling pathways involved as well as on the clinical aspects and safety profiles of JAKinibs approved for the treatment of RA.

4 March 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
Bogdan Silviu UngureanuBogdan Silviu Ungureanu
Bogdan Silviu Ungureanu
CLCristian-Virgil Lungulescu
Cristian-Virgil Lungulescu
DPDaniel Pirici
Daniel Pirici
Adina Turcu-StiolicaAdina Turcu-Stiolica
Adina Turcu-Stiolica
DGDan Ionut Gheonea
Dan Ionut Gheonea
ASAdrian Saftoiu
Adrian Saftoiu
An increasing number of tumor markers have been discovered to have potential efficacy as diagnostic and prognostic tools in gastric cancer. We aimed to assess putative correlations between claudin 18.2 expression and pathological or prognosis features in patients with gastric cancer. MEDLINE, Web of Science, EBSCO, and ClinicalTrials.gov were used to search for relevant studies from their inception to 30 October 2020. Finally, a total of six articles were included in this meta-analysis. Review Manager 5 software was applied to examine the heterogeneity among the studies and to calculate the odds ratio with 95% CI by selecting corresponding models, in evaluating the strength of the relationship. Publication bias test was also conducted. No bias and no significant correlations were found between CLDN 18.2 and TNM stages, Lauren classification, HER2, grading, or overall survival. This meta-analysis expounded that the relationship with CLDN 18.2 and pathological features depends on the percentage of staining of tumor cells for which CLDN 18.2 is considered positive. Our pooled outcomes suggest that targeted therapy for CLDN 18.2 could be effective if certain criteria were established.

8 June 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PKPaweł Kawalec
Paweł Kawalec
ESEwa Stawowczyk
Ewa Stawowczyk
TTTomas Tesar
Tomas Tesar
JSJana Skoupa
Jana Skoupa
Adina Turcu-StiolicaAdina Turcu-Stiolica
Adina Turcu-Stiolica
PDPero Draganic
Pero Draganic
Objectives: The aim of this study was to review the requirements for the reimbursement of biosimilars and to compare the reimbursement status, market share, and reimbursement costs of biosimilars in selected Central and Eastern European (CEE) countries. Methods: A questionnaire-based survey was conducted between November 2016 and January 2017 among experts from the following CEE countries: Bulgaria, Czech Republic (Czechia), Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia, and Romania. The requirements for the pricing and reimbursement of biosimilars were reviewed for each country. Data on the extent of reimbursement of biologic drugs (separately for original products and biosimilars) in the years 2014 and 2015 were also collected for each country, along with data on the total pharmaceutical and total public health care budgets. Results: Our survey revealed that no specific criteria were applied for the pricing and reimbursement of biosimilars in the selected CEE countries; the price of biosimilars was usually reduced compared with original drugs and specific price discounts were common. Substitution and interchangeability were generally allowed, although in most countries they were at the discretion of the physician after a clinical assessment. Original biologic drugs and the corresponding biosimilars were usually in the same homogeneous group, and internal reference pricing was usually employed. The reimbursement status of biosimilars in the majority of the countries was the same and amounted to 100%. Generally, the higher shares of expenditures were shown for the reimbursement of original drugs than for biosimilars, except for filgrastim, somatropin and epoetin (alfa and zeta). The shares of expenditures on the reimbursement of biosimilar products ranged from 8.0% in Estonia in 2014 to 38.1% in Lithuania in 2015, and generally increased in 2015. The share of expenditures on reimbursement of biosimilars in the total pharmaceutical budget differed between the countries, with the highest observed for Hungary and the lowest – for Croatia. Conclusions: The requirements for the pricing and reimbursement of biosimilar products as well as the access of patients to biologic treatment do not differ significantly between the considered CEE countries. Biosimilar drugs significantly influence the reimbursement systems of these countries.

1 April 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SŞSimona Ştefanescu
Simona Ştefanescu
RCRELU COCOS
RELU COCOS
Adina Turcu-StiolicaAdina Turcu-Stiolica
Adina Turcu-Stiolica
BMBeatrice Mahler
Beatrice Mahler
AMAndreea-Daniela Meca
Andreea-Daniela Meca
CPCatalina-Gabriela Pisoschi
Catalina-Gabriela Pisoschi
We evaluated in this cohort study the predictive ability of 23 peripheral blood parameters and ratios for treatment outcomes after the 2-month intensive phase in patients with PTB. In 63 patients out of 90 that turned culture negative, a significant decrease in white blood cell count, neutrophils, monocyte, hemoglobin, platelet, plateletcrit, erythrocyte sedimentation rate, MLR, NLR, PLR and SII values after anti-TB therapy compared to pretreatment was observed (p <0.001). Logistic regression analysis generated a model of predictors consisting of nine covariates. Spearman’s correlation analysis revealed significant positive correlations between NLR with NEU (r = 0.79, p<0.01), SII with NEU (r = 0.846, p<0.01), PLT with SII (r = 0.831, p<0.01), PLT with PCT (r = 0.71, p<0.01) and MPV with P-LCR (r = 0,897, p<0.01) in 63 patients out of 90 that turned culture negative after 2 months of treatment. ROC curve analysis indicated that all areas under the curve (AUC) revealed no statistically significant results, except lymphocyte for culture conversion. In summary, here we observed a set of hematological parameters that declined significantly as the disease was treated in patients that turned culture negative. Despite some limitations, our findings are useful for further studies aiming to identify hematological profiles that could predict the treatment outcome.